Alkermes plc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedProfile
Valuation (TTM)
Market Cap$6.25B
P/E40.90
EV—
P/B3.43
Shares Out166.65M
P/Sales4.00
Revenue$1.56B
EV/EBITDA26.47
Alkermes plc (ALKS) Stock Analysis
Market Cap$6.25B
Current Price$37.48
P/E Ratio40.90
Forward P/E—
PEG Ratio-0.11
EPS$1.43
Book Value$10.92
P/B Ratio3.43
ALKS Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 1.0B
Revenue
1.2B
FY19
1.0B
FY20
1.2B
FY21
1.1B
FY22
1.7B
FY23
1.6B
FY24
1.5B
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
356M
FY23
367M
FY24
242M
FY25
ALKS 52-Week Range
$26.13
$38.91
50-Day MA: $32.58200-Day MA: $30.64
Did you know?
ALKS's revenue grew at a 3.9% CAGR over the last 6 years.
Alkermes plc (ALKS) Financial Summary
Alkermes plc (ALKS) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. The stock currently trades at $37.48 with a market capitalization of $6.25B.
Key valuation metrics include a P/E ratio of 40.90, price-to-book ratio of 3.43, and EPS of $1.43. The company reports a profit margin of 9.8% and return on equity of 8.4%.
ALKS Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $6.25B |
| P/E Ratio | 40.90 |
| EPS | $1.43 |
| P/B Ratio | 3.43 |
| P/S Ratio | 4.00 |
| EV/EBITDA | 26.47 |
| Profit Margin | 9.8% |
| Return on Equity | 8.4% |
| Debt/Equity | 0.04 |
ALKS Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $1.17B | $-196.62M |
| FY20 | $1.04B | $-110.86M |
| FY21 | $1.17B | $-48.17M |
| FY22 | $1.11B | $-158.27M |
| FY23 | $1.66B | $355.76M |
| FY24 | $1.56B | $367.07M |
| FY25 | $1.48B | $241.66M |
Alkermes plc (ALKS) Valuation
Based on GoodMoat's DCF model, Alkermes plc has a fair value estimate of $101.41. At the current price of $37.48, the stock appears 63.0% undervalued relative to our intrinsic value estimate.
ALKS Quality Indicators
Alkermes plc maintains a profit margin of 9.8% and an operating margin of 17.2%. Return on equity stands at 8.4%. The current ratio is 3.55. Debt-to-equity ratio is 0.04.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
ALKS Free Cash Flow
Alkermes plc generated $483.13M in trailing twelve-month free cash flow, representing an FCF yield of 7.73%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
ALKS Shares Outstanding
Alkermes plc has 0.17 billion shares outstanding at a share price of $37.48, giving it a market capitalization of $6.25B.